<DOC>
	<DOCNO>NCT03020745</DOCNO>
	<brief_summary>GSK3389404 develop treatment CHB virus infection . The development goal GSK3389404 establishment finite duration treatment result sustain suppression hepatitis B virus ( HBV ) replication viral antigen production cessation treatment CHB due restoration functional immune response absence high antigen level . This study multicenter , randomize double-Blind ( sponsor un-blinded Part 1 ) , Placebo-controlled Study evaluate safety , tolerability , PK , PD profile GSK3389404 subject CHB aim establish proof-of-mechanism . The study conduct two part . Part 1 conduct single ascend dose ( SAD ) study 5 plan cohort range 30 milligram ( mg ) maximum 240 mg GSK3389404 . Within cohort , subject randomize receive either GSK3389404 placebo 3:1 ratio . Cohorts A , B , C , C1 , D conduct sequential fashion ; Cohort C1 may dose Cohort C parallel Cohort D. Part 2 conduct multiple-dose , dose-ranging study . Subjects randomize different parallel dose level regimens placebo . The dose level Part 2 select review Part 1 safety exceed total monthly dose 480 mg . However , total monthly subcutaneous ( SC ) dose 480 mg explore weekly bi-weekly ( every 2 week ) dose regimen . The total study duration part 1 include screening , treatment , post-treatment follow-up , expect exceed 13 week subject part 2 , include screening , treatment post-treatment follow-up , expect exceed 29 week subject .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) GSK3389404 Chronic Hepatitis B ( CHB ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Subject able understand capable give write informed consent , willing comply protocol requirement , instruction protocolstated restriction , likely complete study plan . Between 18 70 year age , inclusive , time signing informed consent form . A body mass index ( BMI ) 18 30 kilogram ( Kg ) /meter ( m^2 ) , inclusive . Male female satisfy follow : Females reproductive potential permit . Eligible female must meet following criterion : Nonpregnant ( confirm negative serum Human Chorionic Gonadotropin [ hCG ] test ) ; AND Nonlactating screen prior dose ; AND Nonreproductive potential define least one follow condition : Premenopausal females without reproductive potential define Documented salpingectomy , Hysterectomy Documented bilateral oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea . A blood sample simultaneous FollicleStimulating Hormone ( FSH ) estradiol level may collect discretion investigator site confirm nonreproductive potential . Male subject female partner childbearing potential must agree meet one contraception requirement time first dose study treatment final Followup visit . Vasectomy . Male condom plus partner 's use one contraceptive option meet Standard Operating Procedure ( SOP ) effectiveness criterion include &lt; 1 percent rate failure per year , state product label : Contraceptive subdermal implant , Intrauterine device intrauterine system , Combined estrogen progestogen oral contraceptive , Injectable progestogen , Contraceptive vaginal ring , Percutaneous contraceptive patch . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Documented chronic HBV infection , define positive serum HBsAg &gt; =6 month prior screen . Subjects HBV treatment history follow : Part 1 : Treatment naive prior treatment interferon ( pegylated non pegylated ) must end least 12 month prior Baseline visit ( Day 1 predose ) and/or nucleos ( ) ide analogue therapy must end least 6 month prior Baseline visit . Part 2 : Subjects CHB receive stable nucleos ( ) ide analogue therapy , define change nucleos ( ) ide regimen least 6 month prior screen plan change stable regimen duration study . Plasma HBV DNA concentration : Phase I : &gt; =20,000 international unit ( IU ) /mL HBeAgpositive subject . &gt; =2000 IU/mL HBeAgnegative subject . Part 2 : HBV DNA must adequately suppress , define plasma serum HBV DNA &lt; low limit quantification ( LLOQ ) . Serum HBsAg concentration &gt; 50 IU/mL . Alanine aminotransferase ( ALT ) concentration : Part 1 : ALT &lt; 5 X Upper Limit Normal ( ULN ) . Part 2 : ALT &lt; =ULN . Medical history : History active diagnosis liver disease CHB , autoimmune hepatitis , nonalcoholic fatty liver disease/non alcoholic steatohepatitis , hemochromatosis , liver failure . History clinical evidence hypertension , significant unstable cardiac disease ( e.g. , prolonged QT syndrome [ torsade de point ] , angina , congestive heart failure , myocardial infarction , diastolic dysfunction , significant arrhythmia , coronary heart disease and/or clinically significant ECG abnormality ) . Uncontrolled history difficult control hypertension . History , active diagnosis , primary secondary renal disease ( e.g. , renal disease secondary diabetes , hypertension , vascular disease , etc. ) . History extrahepatic disorder possibly relate HBV immune complex ( e.g. , glomerulonephritis polyarteritis nodosa ) . History bleed diathesis coagulopathy . History suspect presence vasculitis . History Gilbert 's Syndrome . History malignancy within past 5 year exception specific cancer cure surgical resection ( e.g. , skin cancer ) , subject evaluation possible malignancy eligible . History of/sensitivity GSK3389404 component thereof history drug allergy , opinion investigator medical monitor , contraindicate participation . Confirmed suspect hepatocellular carcinoma ( HCC ) evidence : Alphafetoprotein concentration &gt; =200 nanogram ( ng ) /mL . If screen alphafetoprotein concentration &gt; =50 ng/mL &lt; 200 ng/mL , absence liver mass must document image within 6 month randomization . Liver cirrhosis evidence cirrhosis determine follow : Positive liver biopsy ( i.e. , Metavir Score F4 ) within 12 month screen . Fibroscan &gt; 12 kilopascals ( kPa ) within 12 month screen . ASTPlatelet Index ( APRI ) &gt; 2 FibroSure result &gt; 0.7 within 12 month screen . For subject without test cirrhosis timeframes , APRI FibroSure perform screening period rule cirrhosis . A positive Hepatitis C Virus ( HCV ) antibody test . A positive Human Immunodeficiency Virus ( HIV ) antibody test . Positive Hepatitis D Virus ( HDV ) antibody test . Laboratory result follow : Total bilirubin concentration &gt; 1.25 X ULN . Serum albumin concentration &lt; 3.5 gram ( g ) /deciliter ( dL ) . International normalized ratio ( INR ) &gt; 1.25 . Platelet count &lt; 140 X 10^9/L . Serum creatinine concentration great ULN . Glomerular Filtration Rate ( GFR ) &lt; 90 mL/min calculate Chronic Kidney Disease Epidemiologic Collaboration ( CKDEPI ) formula . Subjects GFR &lt; 90 mL/min &gt; = 80 mL/min may consider consultation GlaxoSmithKline medical monitor . Urine Albumin Creatinine Ratio ( ACR ) &gt; =0.03 mg/mg . In event ACR threshold , eligibility may confirm second measurement . Positive test blood urine . In event positive test , test may repeat , repeat negative urine microscopy reveals &lt; 5 RBC per HighPower Field ( HPF ) , subject consider eligible . Fridericia 's QT correction formula ( QTcF ) &gt; =450 millisecond ( msec ) ( mean triplicate measurement ) . Currently take , take within 3 month screen , immunosuppressing drug ( e.g. , prednisone ) , short course therapy ( &lt; =2 week ) . Current alcohol use judge investigator potentially interfere participant compliance . A positive prestudy treatment screen unwillingness refrain use illicit drug adhere protocolstated restriction participate study . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 5 halflives ( know ) twice duration ( know ) biological effect study treatment ( whichever longer ) 90 day ( halflife duration unknown ) . Prior treatment oligonucleotide small interfere ribonucleic acid ( RNA ) ( siRNA ) within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>GSK3389404</keyword>
</DOC>